U.S. Markets close in 6 hrs 2 mins

Analysts Are Mostly Positive on BioMarin Pharmaceutical in March

Margaret Patrick
Analysts Are Mostly Positive on BioMarin Pharmaceutical in March

How Major Rare Disease Pharma Stocks Are Positioned in March(Continued from Prior Part)Analysts’ recommendations and target priceWall Street analysts expect a potential upside of 32.04% for BioMarin Pharmaceutical (BMRN) based on the stock’s